| P50 | author | H Ozdemir | Q73819086 |
| | Mehmet Haberal | Q90797849 |
| P2093 | author name string | G Moray | |
| | M Haberal | |
| | S Aktas | |
| | T Colak | |
| | H Karakayali | |
| | E Baskin | |
| | S Sevmis | |
| P2860 | cites work | Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients | Q33243379 |
| | Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation | Q33348750 |
| | Role of anti-interleukin-2 receptor antibodies in kidney transplantation | Q34403566 |
| | Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 |
| | Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. | Q42679476 |
| | Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation | Q44064648 |
| | The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. | Q44461526 |
| | Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation | Q44662215 |
| | The use of daclizumab as induction therapy in combination with tacrolimus and mycophenolate mofetil in recipients with previous transplants | Q44712179 |
| | Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials | Q47242957 |
| | The effect of Daclizumab in a high-risk renal transplant population | Q73117712 |
| | Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection | Q73212229 |
| | Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation | Q74015527 |
| | Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients | Q74348272 |
| | Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) | Q74416112 |
| | Risk factors for chronic rejection--a clinical perspective | Q74701733 |
| | Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group | Q78106881 |
| | Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study | Q79576315 |
| | Efficacy of anti-IL-2 receptor antibodies compared to no induction and to antilymphocyte antibodies in renal transplantation | Q80469046 |
| | Renal scintigraphy findings in allograft recipients with increased resistance index on Doppler sonography | Q80664873 |
| P433 | issue | 2 | |
| P304 | page(s) | 453-457 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Transplantation Proceedings | Q7834825 |
| P1476 | title | Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation | |
| P478 | volume | 43 | |